Nvidia set to lose $180 billion in market value today as Meta weighs Google chips
HINGHAM, Mass. - Microbot Medical Inc. (NASDAQ:MBOT) announced Wednesday that its LIBERTY Endovascular Robotic System is now commercially available in the United States through a Limited Market Release (LMR). The medical device company, with a market capitalization of approximately $136 million, has seen its stock price more than double over the past year with a 115% return.
The LIBERTY system, which received FDA 510(k) clearance in September, is being introduced to selected high-volume procedure regions where preliminary demand has already been established. The company describes the system as the first FDA-cleared single-use, remotely operated robotic system for peripheral endovascular procedures. According to InvestingPro data, Microbot Medical holds more cash than debt on its balance sheet, potentially providing financial flexibility as it enters this commercialization phase.
According to the press release statement, the LMR will focus on gathering real-world insights from potential high-volume users to guide future growth and ensure consistent quality and performance. The company plans a Full Market Release during the Society of Interventional Radiology conference in April 2026.
"We are excited to enter the commercialization phase of LIBERTY," said Harel Gadot, CEO, President and Chairman of Microbot Medical.
Since receiving FDA clearance, the company reports it has secured a third-party logistics partner and expanded its commercial leadership team to support the limited release.
The LIBERTY system is designed for precision, efficiency and safety in endovascular procedures, according to the company. Microbot Medical states that feedback from physicians and hospital administrators has been positive, validating their decision to proceed with the limited release.
The company's announcement comes approximately two months after receiving regulatory clearance for the system.
In other recent news, Microbot Medical has reported several significant developments. The company raised approximately $25.2 million through the exercise of preferred investment options, marking the first closing of its two-part offering. Investors purchased over 12 million shares of common stock, with prices ranging from $1.50 to $2.13 per share. Additionally, Microbot Medical announced a new partnership with a U.S.-based logistics firm to support the commercialization of its LIBERTY Endovascular Robotic System, which is FDA-cleared. This strategic move is aimed at facilitating the system's limited market release in the fourth quarter of 2025, with a broader launch planned for April 2026.
Furthermore, the company has issued new equity options and common stock through private placements, including the exercise of 600,000 series H preferred investment options. H.C. Wainwright has reiterated its Buy rating for Microbot Medical, maintaining a price target of $12.00 following these developments. The firm also highlighted the company's recent patent approval in Japan, which covers the core technology of the LIBERTY System. These recent activities underscore Microbot Medical's ongoing efforts to expand its market presence and technological capabilities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.